Ascendis Pharma (ASND) Tops Q1 EPS by 9c
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Join SI Premium – FREE
Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of EUR0.27, EUR0.09 better than the analyst estimate of EUR0.18. Revenue for the quarter came in at EUR246.6 million versus the consensus estimate of EUR269.95 million.
For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cencora says Walgreens volumes shift, reaffirms guidance, shares sink
- Barclays sees upside for Alibaba, Churchill Downs
- Okta upgraded as AI security opportunity boosts outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
